ESTRO 2024 - Abstract Book

S631

Clinical - Breast

ESTRO 2024

77. Martin MG, Welch JS, Luo JQ, Ellis MJ, Graubert TA, Walter MJ. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast cancer research and treatment. 2009;118(3):593-8.

78. Kaplan HG, Malmgren JA, Atwood MK. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. BMC cancer. 2011;11. 79. Cordeiro PG, Ghione P, Ni A, Hu Q, Ganesan N, Galasso N, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2020;73(5):841-6.

80. Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecologic oncology. 2005;96(1):222-6.

81. Choi S, Lee YJ, Jeong JH, Jung J, Lee JW, Kim HJ, et al. Risk of endometrial cancer and frequencies of invasive endometrial procedures in young breast cancer survivors treated with tamoxifen: a nationwide study. Frontiers in oncology. 2021;11:1951. 82. de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, et al. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. JNCI: Journal of the National Cancer Institute. 2021;113(9):1203-11.

83. Abdulkareem I, Zurmi I. Review of hormonal treatment of breast cancer. Nigerian journal of clinical practice. 2012;15(1).

84. Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast (Edinburgh, Scotland). 2017;35:122-9.

85. Grantzau T, Thomsen MS, Væth M, Overgaard J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014;111(3):366-73.

86. Lee B, Lee S, Sung J, Yoon M. Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT. Journal of Radiological Protection. 2014;34(2):325-31.

87. Haciislamoglu E, Cinar Y, Gurcan F, Canyilmaz E, Gungor G, Yoney A. Secondary cancer risk after whole-breast radiation therapy: Field-in-field versus intensity modulated radiation therapy versus volumetric modulated arc therapy. British Journal of Radiology. 2019;92(1102). 88. Aziz MH, Schneider F, Clausen S, Blank E, Herskind C, Afzal M, et al. Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy (IORT) with low-energy x rays? Radiation oncology. 2011;6(1):1-9. 89. Vaidya JS, Bulsara M, Saunders C, Flyger H, Tobias JS, Corica T, et al. Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT A Randomized Clinical Trial in Early Breast Cancer. JAMA Oncology. 2020;6(7):e200249-e.